Sustained-release leuprorelin preparation

Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula wherein X represents an acyl group; R 1 , R 2 and R 4 each represents an aromatic cyclic group; R 3 represents a D-amino acid residue or a group of the formula wherein R 3 ' is a heterocyclic group; R 5 represents a group of the formula -(CH 2 ) n -R 5 ' wherein n is 2 or 3, and R 5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group; R 6 represents a group of the formula -(CH 2 ) n -R 6 ' wherein n is 2 or 3, and R 6 ' is an amino group which may optionally be substituted; R 7 represents a D-amino acid residue or an azaglycyl residue; and Q represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group. The sustained-release preparation shows a constant release of the peptide over a long time without an initial burst.

Description: The present invention relates to a method of producing sustained-release preparation of leuprorelin or a salt thereof. The prior art includes, as disclosed in EP-A-481,732, a sustained-release preparation comprising a drug, a polylactic acid and a glycolic acid-hydroxycarboxylic acid [HOCH(C 2-8 alkyl)COOH] copolymer. The disclosed process comprises preparing a W/O emulsion consisting of an internal water phase comprising an aqueous solution of a physiologically active peptide and an external oil phase comprising a solution of a biodegradable polymer in an organic solvent, adding said W/O emulsion to water or an aqueous medium and processing the resulting W/O/W emulsion into sustained-release microcapsules (drying-in-water method). EP-A-52510 describes a microcapsule comprising a hormonally active polypeptide, a biodegradable polymer and a polymer hydrolysis control agent. The disclosed process for its production is a coacervation process which comprises adding a coacervation agent to a W/O emulsion consisting of an aqueous solution of the polypeptide as the internal water phase and a halogenated organic solvent as the oil phase to provide microcapsules. GB-A-2209937 describes a pharmaceutical composition comprising a polylactide, a polyglycolide, a lactic acid-glycolic acid copolymer or a mixture of these polymers and a water-insoluble peptide. Also disclosed is a production process which comprises dispersing a salt of the water-insoluble peptide in a solution of said polylactide, polyglycolide, a lactic acid-glycolic acid copolymer or a mixture of these polymers, removing the solvent by evaporation and molding the resulting mixture into solid particles. EP-A-58481 describes a process for producing a pharmaceutical composition comprising a polylactide and an acid-stable polypeptide which, for instance, comprises dissolving tetragastrin hydrochloride and a polylactide in aqueous dioxane, casting the solution into a film and evaporating the solvent. EP-A-0467389 teaches a technology for providing a drug delivery system for proteins and polypeptides by the polymer precipitation technique or the microsphere technique. However, this literature contains no specific disclosure about a system containing an LH-RH derivative. The luteinizing hormone-releasing hormone, known as LH-RH (or GnRH), is secreted from the hypothalamus and binds to receptors on the pituitary gland. The LH (luteinizing hormone) and FSH (folicle stimulating hormone), which are released thereon, act on the gonad to synthesize steroid hormones. As derivatives of LH-RH, the existence of both agonistic and antagonistic peptides is known. When a highly agonistic peptide is repeatedly administered, the available receptors are reduced in number so that the formation of gonad-derived steroidal hormones is suppressed. Therefore, LH-RH derivatives are expected to be of value as therapeutic agents for hormone-dependent diseases such as prostate cancer, benign prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, mammary cancer, etc. or as contraceptives. Particularly, the problem of histamine-releasing activity was pointed out for LH-RH antagonists of the so-called first and second generations (The Pharmaceuticals Monthly 32 , 1599-1605, 1990) but a number of compounds have since been synthesized and recently LH-RH-antagonizing peptides having no appreciable histamine-releasing activity have been developed (cf. USP No. 5110904, for instance). In order for any such LH-RH antagonizing peptide to manifest its pharmacological effect, there is a need for a controlled release system so that the competitive inhibition of endogenous LH-RH may be persistent. Moreover, because of histamine-releasing activity which may be low but is not non-existent in such peptides, a demand exists for a sustained-release preparation with an inhibited initial burst immediately following administration. Particularly, in the case of a sustained-release (e.g. 1-3 months) preparation, it is important to insure a more positive and constant release of the peptide in order that the desired efficacy may be attained with greater certainty and safety. At the same time, there is a long felt need for a method of producing a sustained-release preparation having a high peptide trap rate for the physiologically active peptide leuprorelin. According to the present invention,'there is provided a method of producing microcapsules comprising a sustained-release preparation of leuprorelin or a salt thereof which comprises (a) dissolving or suspending leuprorelin or a salt thereof in an organic solvent solution of a biodegradable polymer comprising a copolymer of lactic acid and glycolic acid having a terminal carboxyl group; (b) adding the mixture to an aqueous medium to provide an O/W emulsion; and (c) transforming the emulsion into microcapsules by removal of the organic solvent. According to the invention, the leuprorelin may be in the form of leuprorelin acetate. Furthermore, according to the invention, the aqueous medium of step (b) may be polyvinyl alcohol in water. The sustained-release preparation prepared according to the method of the invention may comprise the copolymer of lactic acid and glycolic acid having a weight average molecular weight of about 5,000 to 25,000, as determined by GPC. According to a further embodiment, the copolymer has a dispersion value of about 1.2 to 4.0. According to a further aspect of the invention, the proportion of the leuprorelin physiologically active peptide ranges from about 0.01 to 50% (w/w) based on the biodegradable polymer in the sustained-release preparation. In the present invention, the leuprorelin or a salt thereof shows LH-RH antagonistic activity and is effective for the treatment of hormone-dependent diseases such as prostatic cancer, prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, mammary cancer, etc. or for contraception. The leuprorelin can be used in the form of a salt, preferably a pharmacologically acceptable salt. The peptide has basic groups such as amino, so possible salts include salts with inorganic acids (e.g. hydrochloric acid, sulfuric acid, nitric acid, etc.) or organic acids (e.g. carbonic acid, hydrogen carbonic acid, succinic acid, acetic acid, propionic acid, trifluoro-acetic acid, etc.). The leuprorelin may be in the form of a metal complex compound (e.g. copper complex, zinc complex, etc.). The preferred salts of leuprorelin are salts with organic acids (e.g. carbonic acid, hydrogen carbonic acid, succinic acid, acetic acid, propionic acid, trifluoroacetic acid, etc.). The most preferred is the acetate. In the sustained-release preparation, the proportion of the leuprorelin may range from about 0.01 to about 50% (w/w) based on the biodegradable polymer. The preferred range is about 0.1 to about 40% (w/w) and a more preferred range in about 1 to about 30% (w/w). Determination of the number average molecular weight of the copolymer by end-group determination is as follows. A biodegradable polymer, about 1 to 3 g, was dissolved in a mixture of acetone (25 ml) and methanol (5 ml) and using phenolphthalein as the indicator, the carboxyl groups in the solution were quickly titrated with 0.05N alcoholic potassium hydroxide solution under stirring at room temperature (20°C). The number average molecular weight by end-group determination was then calculated by means of the following equation. Number average molecular weight by end-group determination = 20000 x A/B where A is the mass of biodegradable polymer (g) B is the amount of 0.05N alcoholic potassium hydroxide solution (ml) added to react the titration end-point. The result of the above calculation is referred to as the number average molecular weight by end-group determination. By way of illustration, taking a polymer having a terminal carboxyl group as synthesized from one or more α-hydroxy acids by the non-catalytic dehydrative polycondensation process as an example, the number average molecular weight by end-group determination is approximately equal to the number average molecular weight found by GPC. In contrast, in the case of a polymer substantially not containing free terminal carboxyl groups as synthesized from a cyclic dimer by the ring-opening polymerization process and using catalysts, the number average molecular weight by end-group determination is by far greater than the number average molecular weight by GPC determination. By this difference, a polymer having a terminal carboxyl group can be clearly discriminated from a polymer having no terminal carboxyl group. Thus, the term 'biodegradable polymer having a terminal carboxyl group' is used herein to mean a biodegradable polymer showing a substantial agreement between the number average molecular weight by GPC determination and the number average molecular weight by end-group determination. Whereas the number average molecular weight by end-group determination is an absolute value, the number average molecular weight by GPC determination is a relative value which varies according to analytical and procedural conditions (such as types of mobile phase and column, reference substance, selected slice width, selected baseline, etc.). Therefore, the two values cannot be numerically correlated by generalization. However, the term 'substantial agreement' between the number average molecular weight by GPC determination and the number average molecular weight by end-group determination means that the number average molecular weight found by end-group determination is about 0.4 to 2 times, more preferably about 0.5 to 2 times, most preferably about 0.8 to 1.5 times, the number average molecular weight by GPC determination. The term by far greater' as used above means that the number average molecular weight by end-group determination is about twice or greater than the number average molecular weight by GPC determination. The preferred polymer for the purpose of the present invention is a polymer showing a substantial agreement between the number average molecular weight by GPC determination and the number average molecular weight by end-group determination. The biodegradable polymer according to the invention is a copolymer of lactic acid and glycolic. acid. The mode of polymerization may be random, block or graft. Where the above-mentioned α-hydroxy acids have an optical activity center within the molecule, any of the D-, L- and DL- forms can be employed. Polylactic acid for use in the present invention may be whichever of L- and D- compounds and any mixture thereof. Preferred is a species with D-/L-ratio (mole %) in the range of about 75/25 through about 20/80. The more preferred D-/L-ratio (mole %) of polylactic acid is about 60/40 through about 25/75. The most advantageous D/L-ratio (mole %) of polylactic acid is about 55/45 through about 25/75. The weight average molecular weight of polylactic acid is preferably in the range of about 1,500 to about 30,000, more preferably about 2,000 to about 20,000 and still more preferably about 3,000 to about 15,000. The dispersion value of polylactic acid is preferably about 1.2 to about 4.0 and more desirably about 1.5 to about 3.5. Polylactic acid can be synthesized by two known alternative processes, namely a process involving a ring-opening polymerization of lactide which is a dimer of lactic acid and a process involving a dehydrative polycondensation of lactic acid. For the production of a polylactic acid of comparatively low molecular weight for use in the present invention, the process involving a direct dehydrative polycondensation of lactic acid is preferred. This process is described in, for example, Japanese laid-open patent application 28521/1986. A copolymer of lactic acid and glycolic acid is used as the biodegradable polymer and preferably its polymerization ratio (lactic acid/glycolic acid) (mole %) is about 100/0 to about 40/60. The more preferred ratio is about 90/10 to about 50/50. The weight average molecular weight of said copolymer is preferably about 5,000 to about 25,000. The more preferred range is about 7,000 to about 20,000. The degree of dispersion (weight average molecular weight/number average molecular weight) of said copolymer is preferably about 1.2 to about 4.0. The more preferred range is about 1.5 to about 3.5. The above-mentioned copolymer of lactic acid and glycolic acid can be synthesized by the known technology, for example by the process described in Japanese laid-open patent application 28521/1986. The decomposition and disappearance rate of a copolymer of lactic acid and glycolic acid varies greatly with the composition and molecular weight by generally speaking, the smaller the glycolic acid fraction, the lower is the decomposition and disappearance rate. Therefore, the duration of drug release can be prolonged by reducing the glycolic acid fraction or increasing the molecular weight. Conversely, the duration of release can be diminished by increasing the glycolic acid fraction or reducing the molecular weight. To provide a long-term (e.g. 1-4 months) sustained-release preparation, it is preferable to use a copolymer of lactic acid and glycolic acid with a polymerization ratio within the above-mentioned range and a weight average molecular weight within the above-mentioned range. With a copolymer of lactic acid and glycolic acid having a higher decomposition rate than that within the above ranges for polymerization ratio and weight average molecular weight, it is difficult to control the initial burst. On the contrary, with a copolymer of lactic acid and glycolic acid showing a lower decomposition rate than that within said ranges for polymerization ratio and weight average molecular weight, periods in which the drug will not be released in an effective amount tend to occur. In this specification, the weight average molecular weight and the degree of dispersion mean the molecular weight in terms of polystyrene as determined by gel permeation chromatography (GPC) using 9 polystyrenes with the weight average molecular weights of 120,000, 52,000, 22,000, 9,200, 5,050, 2950, 1,050, 580 and 162 as references and the dispersion value calculated using the same molecular weight, respectively. The above determination was carried out using GPC Column KF804 L x 2 (Showa Denko), RI Monitor L-3300 (Hitachi) and, as the mobile phase, chloroform. In the method of the invention, leuprorelin is dissolved or suspended in an organic solvent solution of a copolymer of lactic acid and glycolic acid. The solvent which is substantially immiscible with water is a solvent which is not only substantially immiscible with water and capable of dissolving the biodegradable polymer but is one which renders the resultant polymer solution capable of dissolving the leuprorelin. Preferably, it is a solvent with a solubility in water of not more than 3% (w/w) at atmospheric temperature (20°C). The boiling point of such solvent is preferably not higher than 120°C. The solvent, thus, includes halogenated hydrocarbons (e.g. dichloromethane, chloroform, chloroethane, trichloroethane, carbon tetrachloride, etc.), alkyl ethers of 3 or more carbon atoms (e.g. isopropyl ether etc.), fatty acid alkyl (of 4 or more carbon atoms) esters (e.g. butyl acetate etc.), aromatic hydrocarbons (e.g. benzene, toluene, xylene, etc.) and so on. These solvents can be used in a suitable combination of 2 or more species. The more preferred solvents are halogenated hydrocarbons (e.g. dichloromethane, chloroform, chloroethane, trichloroethane, carbon tetrachloride, etc.). The most preferred is dichloromethane. Removal of the solvent can be effected by the per se known procedures. For example, the method comprising evaporating the solvent at atmospheric pressure or under gradual decompression with constant stirring by means of a propeller mixer or a magnetic stirrer or the method comprising evaporating the solvent under controlled vacuum in a rotary evaporator can be employed. Referring to the method of the invention for the production of the sustained-release preparation, dissolving the leuprorelin and the biodegradable polymer with a terminal carboxyl group means achieving conditions such that the resultant solution shows no visually observable residue of undissolved peptide at ordinary temperature (20°C). In this ternary system considering of the leuprorelin, biodegradable polymer and solvent, the amount of peptide which can be dissolved depends on the number of a terminal carboxyl groups per unit weight of the biodegradable polymer. In case the peptide and the terminal carboxyl group interact in the ratio of 1 to 1, the same molar amount of the peptide as that of the terminal carboxyl group can be dissolved in theory. Therefore, generalization is difficult according to the combination of the solvent and the molecular weight of the peptide and the biodegradable polymer. However, in producing sustained-release preparations, the peptide may be dissolved in the range of about 0.1 to about 100% (w/w), preferably about 1 to about 70% (w/w), most preferably about 2 to about 50% (w/w), with respect to the biodegradable polymer which is dissolved in the solvent. The preferred process for the production of the sustained-release preparation of the present invention is a microencapsulating process utilizing the drying-in-water technique or the phase separation technique, which is described below, or any process analogous thereto. Thus, leuprorelin is added to a solution of the biodegradable polymer in an organic solvent in the final weight ratio mentioned hereinbefore for such peptide to prepare an organic solvent solution containing the leuprorelin and biodegradable polymer which is a copolymer of lactic acid and glycolic acid. In this connection, the concentration of the biodegradable polymer in the organic solvent varies according to the molecular weight of the biodegradable polymer and the type of organic solvent but is generally selected from the range of about 0.01 to about 80% (w/w). The preferred range is about 0.1 to about 70% (w/w). The still more preferred range is about 1 to about 60% (w/w). Then this organic solvent solution containing the leuprorelin and the biodegradable polymer (oil phase) is added to a water phase to prepare an O(oil phase)/W (water phase) emulsion. The solvent of the oil phase is then evaporated off to provide microcapsules. The volume of the water phase for this procedure is generally selected from the range of about 1 to about 10000 times the volume of the oil phase. The preferred range is about 2 to about 5000 times and the still more preferred range is about 5 to about 2000 times. An emulsifier may be added to the above water phase. The emulsifier may generally be any substance that contributes to the formation of a stable O/W emulsion. Thus, there can be mentioned anionic surfactants (sodium oleate, sodium stearate, sodium lauryl sulfate, etc.), nonionic surfactants (polyoxyethylene-sorbitan fatty acid esters [Tween 80 and Tween 60, Atlas Powder], polyoxyethylene-castor oil derivatives [HCO-60 and HCO-50, Nikko Chemicals], etc.), polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, hyaluronic acid and so on. These emulsifiers can be used independently or in combination. The concentration may be selected from the range of about 0.001 to about 20% (w/w). The preferred range is about 0.01 to about 10% (w/w) and the still more preferred range is about 0.05 to about 5% (w/w). The resultant microcapsules are recovered by centrifugation or filtration and washed with several portions of distilled water to remove the free peptide, vehicle and emulsifier from the surface, then redispersed in distilled water or the like and lyophilized. Then, if necessary, the microcapsules are heated under reduced pressure to further remove the residual water and organic solvent from within the microcapsules, Preferably, this procedure is carried out by heating the microcapsule at a temperature somewhat (5°C or more) above the medium glass transition temperature of the biodegradable polymer as determined with a differential scanning calorimeter at temperature increments of 10 to 20°C/min., generally for not more than 24 hours, after the microcapsules have reached the target temperature. In the production of microcapsules by the phase separation technique, a coacervation agent is gradually added to a solution of the leuprorelin and biodegradable polymer in an organic solvent with constant stirring so that the biodegradable polymer may separate out and solidify. This coacervation agent is added in a volume of about 0.01 to about 1000 times the volume of the organic solvent solution of leuprorelin and biodegradable polymer. The preferred range is about 0.05 to about 500 times and the still more preferred range is about 200 times. The coacervation agent should be a compound of polymer, mineral oil or vegetable oil type which is miscible with the solvent for the biodegradable polymer yet which does not dissolve the polymer. Specifically, silicone oil, sesame oil, soybean oil, corn oil, cottonseed oil, coconut oil, linseed oil, mineral oil, n-hexane, n-heptane, etc. can be mentioned. These substances can be used in combination. The resultant microcapsules are recovered by filtration and washed repeatedly with heptane or the like to remove the coacervation agent. Then, the free peptide and solvent are removed by the same procedure as described for the drying-in-water technique. In the drying-in-water technique or in the coacervation technique, an aggregation inhibitor may be added so as to prevent aggregation of particles. The aggregation inhibitor includes water-soluble polysaccharides such as mannitol, lactose, glucose, starch (e.g. corn starch), etc., glycine, proteins such as fibrin, collagen, etc., and inorganic salts such as sodium chloride, sodium hydrogen phosphate and so on. In the production of microcapsules by the spray drying technique, said organic solvent solution of leuprorelin and biodegradable polymer is ejected in a mist form through a nozzle into the drying chamber of a spray drier to evaporate the organic solvent from the finely-divided liquid droplets in a brief time to provide fine microcapsules. The nozzle may be a two-fluid nozzle, pressure nozzle, rotary disk nozzle and so on. It is advantageous to the process to spray an aqueous solution of said aggregation inhibitor from another nozzle for the prevention of intercapsule aggregation in coordination with said spray of the organic solvent solution of leuprorelin and biodegradable polymer. If necessary, the residual water and organic solvent are removed by heating the resultant microcapsules under reduced pressure in the same manner as described hereinbefore. The microcapsules can be administered as they are or as processed into various pharmaceutical preparations for administration by routes other than peroral (e.g. intramuscular, subcutaneous and intraorgan injections or implants, nasal, rectal or uterine transmucosal delivery systems, and so on) or for oral administration (e.g. solid preparations such as capsules (e.g. hard capsules, soft capsules, etc.), granules, powders, etc. and liquid preparations such as syrups, emulsions, suspensions and so on). To process the microcapsules for injection, for instance, the microcapsules can be formulated with a dispersant (e.g. a surfactant such as Tween 80, HCO60, etc., carboxymethylcellulose, a polysaccharide such as sodium alginate, etc.), a preservative (e.g. methylparaben, propylparaben, etc.), or an isotonizing agent (e.g. sodium chloride, mannitol, sorbitol, glucose, etc.) to prepare an aqueous suspension or they may be dispersed in a vegetable oil such as sesame oil, corn oil or the like to provide an oil suspension for such controlled release injection. The particle size of the microcapsules for use as an injectable suspensions need only be in the range satisfying the dispersibility and needle passage requirements and may for example range from about 0.1 to about 500 µm. The preferred particle size range is about 1 to about 300 µm and the still more preferred range is about 2 to about 200 µm. For providing the microcapsules as a sterile product, the whole production process is subjected to sterility control, the microcapsules are sterilized by gamma-ray irradiation or a preservative is added, although these are not exclusive procedures. The sustained-release preparation of the present invention can be administered as an intramuscular, subcutaneous or intraorgan injection or implant, a transmucosal delivery system for application to the nasal cavity, rectum or uterus, or an oral preparation (e.g. a solid preparation such as a capsule (e.g. hard or soft), granule, powder, etc. or a liquid preparation such as syrup, emulsion, suspension, etc.). The sustained-release preparation of the present invention has low toxicity and can be used safely in mammalian animals (e.g. man, bovine, swine, canine, feline, murine, rat and rabbit). The dosage of the sustained-release preparation is dependent on the content of the leuprorelin, final dosage form, the duration of release of the peptide, the object of treatment (such as hormone-dependent diseases, e.g. prostatic cancer, prostatomegaly, endometriosis, metrofibroma, precocious puberty, mammary cancer, etc., or for contraception) and the subject animal species, but in any case it is necessary that an effective amount of peptide is successfully delivered. The unit dosage of the leuprorelin, taking a one-month delivery system as an example, can be selected advantageously from the range of about 0.01 to about 100 mg/kg body weight for an adult human. The preferred range is about 0.05 to about 50 mg/kg body weight. The most preferred range is about 0.1 to about 10 mg/kg body weight. The unit dosage of the sustained-release preparation per adult human can therefore be selected from the range of about 0.1 to about 500 mg/kg body weight. The preferred range is about 0.2 to about 300 mg/kg body weight. The frequency of administration may range from once in a few weeks, monthly or once in a few months, for instance, and can be selected according to the content of the leuprorelin final dosage form, designed duration of release of the peptide, the disease to be managed and the subject animal. The following reference and working examples are intended to describe the invention in further detail and should by no means be construed as defining the scope of the invention. (Unless otherwise specified, % means % by weight). Abbreviations used hereinafter have the following definitions: BOC: tert-butoxycarbonyl FMOC: 9-fluorenylmethoxycarbonyl Cbz: Benzyloxycarbonyl Reference Example 1 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 300 g of 90% aqueous solution of D,L-lactic acid and 100 g of 90% aqueous solution of L-lactic acid and the charge was heated under reduced pressure in a nitrogen gas stream from 100°C/500 mmHg to 150°C/30 mmHg over a period of 4 hours, with the distillate water being constantly removed. The reaction mixture was further heated under reduced pressure at 3-5 mmHg/150-180°C for 7 hours, after which it was cooled to provide an amber-colored polylactic acid. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the above polylactic acid were 3,000; 1,790 and 1,297, respectively. These data showed that the polymer had terminal carboxyl groups. Reference Example 2 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 500 g of 90% aqueous solution of D,L-lactic acid and the charge was heated under reduced pressure in a nitrogen gas stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 4 hours, with the distillate water being constantly removed. The reaction mixture was the further heated under reduced pressure at 3-5 mmHg/150-180°C for 12 hours, after which it was cooled to provide an amber-colored polylactic acid. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the above polylactic acid was 5,000; 2,561; and 1,830, respectively. These data showed that the polymer had terminal carboxyl groups. Reference Example 3 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 300 g of 90% aqueous solution of D,L-lactic acid and 100 g of 90% aqueous solution of L-lactic acid and the charge was heated under reduced pressure in a nitrogen gas stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 5 hours, with the distillate water being constantly removed. The reaction mixture was further heated under reduced pressure at 5-7 mmHg/150-180°C for 18 hours, after which it was cooled to provide an amber-colored polylactic acid. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the above polylactic acid was 7,500; 3,563; and 2,301, respectively. These data showed that the polymer had terminal carboxyl groups. Reference Example 4 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 300 g of 90% aqueous solution of D,L-lactic acid and 100 g of 90% aqueous solution of L-lactic acid and the charge was heated under reduced pressure in a nitrogen gas stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 5 hours, with the distillate water being constantly removed. The reaction mixture as further heated under reduced pressure at 5-7 mmHg/150-180°C for 26 hours, after which it was cooled to provide an amber-colored polylactic acid. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the above polylactic acid was 9,000; 3,803; and 2,800, respectively. This data showed that the polymer had terminal carboxyl groups. Reference Example 5 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 300 g of 90% aqueous solution of D,L-lactic acid and 100 g of 90% aqueous solution of L-lactic acid and the charge was heated under reduced pressure in a nitrogen gas stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 4 hour with the distillate water being constantly removed. The reaction mixture was further heated under reduced pressure at 3-5 mmHg and 150-180°C for 10 hours; after which it was cooled to provide an amber-colored polylactic acid. This polymer was dissolved in 1,000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight-average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the above polylactic acid was 4,200; 2,192; and 1,572, respectively. These data showed that the polymer had terminal carboxyl groups. Reference Example 6 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 322 g of 90% aqueous solution of D,L.-lactic acid and 133 g of glycolic acid and using a mantle heater (So-go Rikagaku Glass Co.), the charge was heated under reduced pressure in a nitrogen stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 4 hours the distillate water being constantly removed. The reaction mixture was further heated under reduced pressure at 3-30 mmHg/150 - 185°C for 23 hours, after which it was cooled to provide a lactic acid-glycolic acid copolymer. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the resultant lactic acid-glycolic acid copolymer were 10,000; 4,000; and 4,000, respectively. These data showed that the copolymer was a polymer having terminal carboxyl groups. Reference Example 7 A 1000 ml four-necked flask equipped with a nitrogen inlet pipe and condensor was charged with 347 g of 90% aqueous solution of D,L-lactic acid and 266 g of glycolic acid and using a mantle heater (So-go Rikagaku Glass Co.), the.charge was heated under reduced pressure in a nitrogen stream from 100°C/500 mmHg to 150°C/30 mmHg for a period of 5 hours, with the distillate water being constantly removed. The reaction mixture was further heated under reduced pressure at 3 - 30 mmHg/150 - 185°C for 23 hours, after which it was cooled to provide a lactic acid-glycolic acid copolymer. This polymer was dissolved in 1000 ml of dichloromethane and the solution was poured in warm water at 60°C with constant stirring. The resulting pasty polymeric precipitates were collected and dried in vacuo at 30°C. The weight average molecular weight and number average molecular weight, as determined by GPC, and the number average molecular weight, as found by end-group determination, of the resultant lactic acid-glycolic acid copolymer were 10,000; 3,700; and 3,900, respectively. These data showed that the copolymer was a polymer having terminal carboxyl groups. Example 1 Leuprorelin acetate (manufacturer: Takeda Chemical Industries), 400 mg, was added to a solution of 3.6 g of a lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 75/25 (mole %), GPC weight average mol.wt. = 10,000, GPC number average mol.wt. = 4,400 number average mol.wt. by end-group determination = 4,30-0; manufacturer: Wako Pure Chemical (Lot. 880530)) in 8.0 g (60 ml) of dichloromethane to prepare a clear homogenous solution. The resulting solution was cooled to 15°C and poured into 1000 ml of a 0.1% aqueous solution of polyvinyl alcohol previously adjusted to 15°C. The mixture was emulsified using a turbine mixer at 7000 rpm to prepare an O/W emulsion. This O/W emulsion was stirred at room temperature for 3 hours to evaporate the dichloromethane. The oil phase was solidified and collected with a centrifuge (05PR-22, Hitachi) at 2000 rpm. This solid was redispersed in distilled water and further centrifuged to wash off the free drug etc. The collected microcapsules were redispersed in a small quantity of distilled water, followed by addition of 0.3 g of D-mannitol and freeze-drying to provide a powder. Comparative Example 1 Leuprorelin acetate (manufacturer: Takeda Chemical Industries), 400 mg, was added to a solution of 3.6 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 75/25 (mole %), GPC weight average mol.wt. = 18,000, GPC number average mol. wt. = 8,400, number average mol. wt. by end-group determination = 30,000; manufacturer: Boehringer-Ingelheim (Lot. RG752-15057)) in 8.0 g (6.0 ml) of dichloromethane but the leuprorelin acetate could not be successfully dissolved. The sustained-release preparation of the present invention shows a constant release of the leuprorelin over a long time, thus being conducive to a lasting and stable effect. Furthermore, the duration of release of the drug can be easily controlled and excessive release immediately following administration can be inhibited. The sustained-release preparation has excellent dispersibility. Moreover, the preparation is stable (e.g. to light, heat, humidity, colouring) and of low toxicity and, therefore, can be safely administered. In accordance with the production method of the present invention, a sustained-release preparation containing the leuprorelin can be easily obtained in good yield. The thus obtained sustained-release preparation has a smooth surface and is excellent in mobility.

Claims: A method of producing microcapsules comprising a sustained-release preparation of leuprorelin or a salt thereof which comprises (a) dissolving or suspending leuprorelin or a salt thereof in an organic solvent solution of a biodegradable polymer comprising a copolymer of lactic acid and glycolic acid having a terminal carboxyl group; (b) adding the mixture to an aqueous medium to provide an O/W emulsion; and (c) transforming the emulsion into microcapsules by removal of the organic solvent. The method of claim 1 wherein said leuprorelin is in the form of leuprorelin acetate. The method of claim 1 or claim 2 wherein said aqueous medium of step (b) is polyvinyl alcohol in water. A microcapsule which is obtainable by using the method as claimed in any of claims 1 to 3.

Inventors: IGARI YASUTAKA, KAMEI SHIGERU, OGAWA YASUAKI, IGARI, YASUTAKA, KAMEI, SHIGERU, OGAWA, YASUAKI
Applicants: TAKEDA PHARMACEUTICAL, TAKEDA PHARMACEUTICAL COMPANY LIMITED
Application year: 1993
Main classification: A61K38
IPC codes: C07K7, A61K38, A61K9